Abazistobart clinical trials
Also written 609A.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses abazistobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- 609A
- 4
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses abazistobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic SarcomaStatus unknownPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT05193214Written as Recombinant anti-PD-1 humanized monoclonal antibody injectionHow we know
- A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue SarcomaStatus unknownPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT05138146Written as 609AHow we know
- Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in ChinaStatus unknownNot applicableSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT03998345Written as 609AHow we know
- Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609AStatus unknownPhase 1Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT03950297Written as 609AHow we know
Codes
What other systems call abazistobart · ClinicalTrials.gg INT016262
- UNII (FDA) D0H5SB66Q4ABAZISTOBARTOne source FDA
- NCI Thesaurus C172820AbazistobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D0H5SB66Q4 | ABAZISTOBART | One source FDA |
| NCI Thesaurus | C172820 | Abazistobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.